MedTrace Logo

Pharmacokinetics and Relative Bioavailability Study

NCT01521767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-01-27

No results posted yet for this study

Summary

A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

tolterodine tartrate

4 mg single dose of extended release capsules

DRUG

tolterodine tartrate

4 mg single dose of microspheres in powder blend

DRUG

tolterodine tartrate

4 mg single dose of microspheres in powder blend

DRUG

tolterodine tartrate

4 mg single dose of microspheres in powder blend

DRUG

tolterodine tartrate

4 mg single dose of microspheres in powder blend

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01521767 on ClinicalTrials.gov